TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study

TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 238(2022) vom: 01. Mai, Seite 109018
1. Verfasser: Schnabel, A (VerfasserIn)
Weitere Verfasser: Nashawi, M, Anderson, C, Felsenstein, S, Lamoudi, M, Poole-Cowley, J, Lindell, E, Oates, B, Fowlie, P, Walsh, J, Ellis, T, Hahn, G, Goldspink, A, Martin, N, Mahmood, K, Hospach, T, Lj, McCann, Hedrich, C M
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Multicenter Study Bone CNO CRMO Chronic nonbacterial osteomyelitis Pamidronate Response TNF inhibitor Treatment mehr... Diphosphonates Tumor Necrosis Factor Inhibitors OYY3447OMC
Beschreibung
Zusammenfassung:Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Chronic nonbacterial osteomyelitis (CNO) can cause significant morbidity, including bone pain and damage. In the absence of clinical trials, treatments include non-steroidal anti-inflammatory drugs, corticosteroids, TNF-inhibitors (TNFi) and/or bisphosphonates. In a retrospective chart review in the United Kingdom and Germany, we investigated response to TNFi and/or pamidronate. Ninety-one patients were included, receiving pamidronate (n = 47), TNFi (n = 22) or both sequentially (n = 22). Patients with fatigue [p = 0.003] and/or arthritis [p = 0.002] were more frequently treated with TNFi than pamidronate. Both therapies were associated with clinical remission at 6 months, and reduction of bone lesions on MRI at 12 months. While not reaching statistical significance, pamidronate resulted in faster resolution of MRI lesions. Fewer flares were observed with TNFi. Failure to respond to pamidronate was associated with female sex [p = 0.027], more lesions on MRI [p = 0.01] and higher CRP levels [p = 0.03]. Randomized clinical trials are needed to confirm observations and generate evidence
Beschreibung:Date Completed 17.05.2022
Date Revised 20.05.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2022.109018